This article focuses on one of those potential combination therapies: oncolytic viruses (OVs). In the tug-of-war between fire (immune stimulation) and ice (immune suppression), ice usually wins ...

VP-315 is described as a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy that could induce ...

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

Intriguing historical observations that some viral infections can promote cancer remission have led to investigations of the therapeutic potential of oncolytic viruses that replicate, infect and ...

Other proteins such as H-Ras and Rac1 have been shown to mediate oncolytic specificity in certain systems. The NDV genome allows for stable expression of foreign genes while avoiding the problem ...

MSLN-targeted oncolytic adenoviruses show promise for systemic therapy of advanced cancers May 6, 2025 Aiming to develop a systemic therapy for advanced refractory cancers, researchers have designed a ...

Key advancements in Verrica’s pipeline include positive data from a Phase 2 study of VP-315, an oncolytic peptide candidate targeting basal cell carcinoma. Additionally, the company plans to ...